Home/Filings/4/0001968202-24-000115
4//SEC Filing

STAHL NEIL 4

Accession 0001968202-24-000115

CIK 0000872589other

Filed

Aug 11, 8:00 PM ET

Accepted

Aug 12, 4:05 PM ET

Size

16.9 KB

Accession

0001968202-24-000115

Insider Transaction Report

Form 4
Period: 2024-08-08
STAHL NEIL
SVP Res and Dev Sciences
Transactions
  • Sale

    Common Stock

    2024-08-08$1082.69/sh200$216,53855,896 total
  • Sale

    Common Stock

    2024-08-08$1083.76/sh1,006$1,090,26354,890 total
  • Sale

    Common Stock

    2024-08-08$1084.61/sh1,883$2,042,32153,007 total
  • Sale

    Common Stock

    2024-08-08$1085.01/sh1,708$1,853,19751,299 total
  • Sale

    Common Stock

    2024-08-08$1081.83/sh100$108,18356,096 total
  • Sale

    Common Stock

    2024-08-08$1086.15/sh300$325,84550,999 total
  • Gift

    Common Stock

    2024-08-1290050,099 total
Holdings
  • Common Stock

    (indirect: By 401(k))
    5,849
  • Common Stock

    (indirect: By Trust)
    4,605
Footnotes (6)
  • [F1]Represents volume-weighted average price of sales of 100 shares of Company stock on August 8, 2024 at prices ranging from $1,081.75 to $1,081.91. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 8, 2024 at each separate price.
  • [F2]Represents volume-weighted average price of sales of 200 shares of Company stock on August 8, 2024 at prices ranging from $1,082.65 to $1,082.74. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 8, 2024 at each separate price.
  • [F3]Represents volume-weighted average price of sales of 1,006 shares of Company stock on August 8, 2024 at prices ranging from $1,083.27 to $1,083.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 8, 2024 at each separate price.
  • [F4]Represents volume-weighted average price of sales of 1,883 shares of Company stock on August 8, 2024 at prices ranging from $1,084.01 to $1,084.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 8, 2024 at each separate price.
  • [F5]Represents volume-weighted average price of sales of 1,708 shares of Company stock on August 8, 2024 at prices ranging from $1,085.00 to $1,085.79. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 8, 2024 at each separate price.
  • [F6]Represents volume-weighted average price of sales of 300 shares of Company stock on August 8, 2024 at prices ranging from $1,086.14 to $1,086.16. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 8, 2024 at each separate price.

Issuer

REGENERON PHARMACEUTICALS, INC.

CIK 0000872589

Entity typeother

Related Parties

1
  • filerCIK 0001226689

Filing Metadata

Form type
4
Filed
Aug 11, 8:00 PM ET
Accepted
Aug 12, 4:05 PM ET
Size
16.9 KB